1
|
Ahoussougbemey Mele A, Chew C, Ruiz Vega R, Mahmood R, AlRubaye R. Naproxen-Induced Evans Syndrome. Cureus 2023; 15:e34910. [PMID: 36938179 PMCID: PMC10016752 DOI: 10.7759/cureus.34910] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/13/2023] [Indexed: 02/15/2023] Open
Abstract
Evans syndrome is an autoimmune disorder characterized by the simultaneous occurrence of autoimmune hemolytic anemia and immune thrombocytopenic purpura. It can further be classified as primary Evans syndrome when it occurs by itself, or secondary Evans syndrome when it is associated with other autoimmune and lymphoproliferative disorders. Corticosteroids and immunoglobulins are the first-line treatments for primary Evans syndrome, and subsequent options include other immunosuppressive medications. Medical literature provides little information about the triggers of primary Evans syndrome. Knowing such information, however, is essential to recognize, treat and prevent the recurrence of the disease effectively. We report a 68-year-old female who presented with shortness of breath, cough, bruises, scleral icterus, and dark urine after several days of naproxen therapy for pain. Further workup noted direct antiglobulin test positive for IgG, anemia, and thrombocytopenia. Imaging studies showed deep venous thrombosis. She was diagnosed with Evans syndrome and improved following prompt treatment with corticosteroids, anticoagulants, blood transfusion therapies, and discontinuation of naproxen. The prognosis of Evans syndrome is poor, variable, and characterized by relapses. Early diagnosis and treatment are therefore associated with better prognosis. This case is critical because it shines a light on one of the major causes of Evans syndrome, reports a practical approach to treating the condition, and paves the way for future research on Evans syndrome. This case is also the first reported naproxen-induced Evans syndrome in the world's literature.
Collapse
Affiliation(s)
| | - Christopher Chew
- Internal Medicine, Northeast Georgia Medical Center, Gainesville, USA
| | - Ruben Ruiz Vega
- Internal Medicine, Northeast Georgia Medical Center, Gainesville, USA
| | - Riaz Mahmood
- Internal Medicine, Northeast Georgia Medical Center, Gainesville, USA
| | - Riyadh AlRubaye
- Internal Medicine, Northeast Georgia Medical Center, Gainesville, USA
| |
Collapse
|
2
|
Agarwal V, Gupta V, Bhardwaj VK, Singh K, Khullar P, Bakshi MS. Avoiding Hemolytic Anemia by Understanding the Effect of the Molecular Architecture of Gemini Surfactants on Hemolysis. LANGMUIR : THE ACS JOURNAL OF SURFACES AND COLLOIDS 2021; 37:3709-3720. [PMID: 33733792 DOI: 10.1021/acs.langmuir.1c00154] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/12/2023]
Abstract
Hemolytic behavior of a series of different categories of Gemini surfactants was determined in their low concentration range. Cationic Gemini surfactants of different molecular architectures prove to be highly cytotoxic even at 0.1 mM. Anionic and amino acid-based Gemini surfactants were minimally cytotoxic, although their toxicity was concentration-dependent. With respect to monomeric surfactants of comparable hydrocarbon chain lengths, cationic Gemini surfactants were much more toxic than anionic Gemini surfactants. Incubation temperature was another important parameter that significantly drove the hemolysis irrespective of the molecular structure of the surfactant. Results indicated that the surface activity or liquid-blood cell membrane adsorption tendency of a surfactant molecule determined the degree of hemolytic anemia. Greater surface activity induced greater cytotoxicity, especially when the surfactant possessed a stronger ability to interact with the membrane proteins through hydrophilic interactions. That provided cationic Gemini surfactants a higher ability for hemolytic anemia because they were able to interact with an electronegative cell membrane with favorable interactions in comparison to anionic or amino acid-based Gemini surfactants. These findings are expected to help in designing surface-active drugs with a suitable molecular architecture that can avoid hemolytic anemia.
Collapse
Affiliation(s)
- Vandana Agarwal
- Department of Chemistry, Dr. B.R. Ambedkar National Institute of Technology, Jalandhar, Punjab 144011, India
- Department of Chemistry, B.B.K. D.A.V. College for Women, Amritsar, Punjab 143005, India
| | - Vikas Gupta
- Department of Biotechnology, DAV College, Amritsar, Punjab 143001, India
| | - Vimal Kumar Bhardwaj
- Department of Chemistry, Dr. B.R. Ambedkar National Institute of Technology, Jalandhar, Punjab 144011, India
| | - Kultar Singh
- Department of Chemistry, Khalsa College, G. T. Road, Amritsar, Punjab 143002, India
| | - Poonam Khullar
- Department of Chemistry, B.B.K. D.A.V. College for Women, Amritsar, Punjab 143005, India
| | - Mandeep Singh Bakshi
- Department of Chemistry, Natural and Applied Sciences, University of Wisconsin-Green Bay, 2420 Nicolet Drive, Green Bay, Wisconsin 54311-7001, United States
| |
Collapse
|
3
|
Song M, Meng L, Liu X, Yang Y. Feprazone Prevents Free Fatty Acid (FFA)-Induced Endothelial Inflammation by Mitigating the Activation of the TLR4/MyD88/NF-κB Pathway. ACS OMEGA 2021; 6:4850-4856. [PMID: 33644593 PMCID: PMC7905947 DOI: 10.1021/acsomega.0c05826] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 11/30/2020] [Accepted: 01/18/2021] [Indexed: 06/12/2023]
Abstract
Increased levels of free fatty acid (FFA)-induced endothelial dysfunction play an important role in the initiation and development of atherosclerosis. Feprazone is a nonsteroidal anti-inflammatory compound. However, the beneficial effects of feprazone on FFA-induced endothelial dysfunction have not been reported before. In the current study, we found that treatment with feprazone ameliorated FFA-induced cell death of human aortic endothelial cells (HAECs) by restoring cell viability and reducing the release of lactate dehydrogenase (LDH). Importantly, we found that treatment with feprazone ameliorated FFA-induced oxidative stress by reducing the production of mitochondrial reactive oxygen species (ROS). In addition, feprazone prevented FFA-induced expression and secretion of proinflammatory cytokines and chemokines, such as chemokine ligand 5 (CCL5), interleukin-6 (IL-6), and interleukin-8 (IL-8). We also found that feprazone decreased the expression of matrix metalloproteinase-2 (MMP-2) and matrix metalloproteinase-9 (MMP-9). Interestingly, we found that feprazone reduced the expression of cell adhesion molecules, such as vascular cell adhesion molecule-1 (VCAM-1) and intercellular cell adhesion molecule-1 (ICAM-1). Our results also demonstrate that feprazone prevented FFA-induced activation of the toll-like receptor 4 (TLR4)/myeloid differentiation factor 88 (MyD88)/nuclear factor kappa-B (NF-κB) signaling pathway. These findings suggest that feprazone might serve as a potential agent for the treatment of atherosclerosis by improving the endothelial function.
Collapse
|
4
|
Burgos Pratx L, Santoro D, Coca Mogro B, Valiente VL, Camino P, Scordo W, Salamone H. Etoricoxib-induced immune hemolytic anemia: first case presenting acute kidney failure. Transfusion 2019; 59:1657-1660. [PMID: 30865300 DOI: 10.1111/trf.15226] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2018] [Revised: 01/07/2019] [Accepted: 01/13/2019] [Indexed: 11/30/2022]
Abstract
BACKGROUND Etoricoxib is a selective inhibitor of cyclooxygenase 2 used mainly to treat osteoarticular pain. Here, we report the case of a patient who developed acute kidney failure and immune hemolytic anemia after the use of etoricoxib. STUDY DESIGN AND METHODS An 83-year-old female patient developed immune hemolytic anemia and acute kidney failure after treatment with etoricoxib for articular pain. Given the acute kidney failure, she required five hemodialysis sessions. She was discharged after 17 days. The case of immune hemolytic anemia and kidney failure was fully resolved. RESULTS The direct antiglobulin test was not only positive for IgG but also for C3b and C3d, showing a very intense reactivity (++++). The eluate's reactivity was weaker (++) and showed no defined specificity. The investigation of unexpected antibodies in the serum of the patient showed a reactivity pattern similar to the eluate's: weak reactivity without specificity. The serum of the patient was compared to urine and plasma samples of two groups of volunteers. The indirect antiglobulin test showed only a very strong reactivity with the urine samples of the volunteers who had received etoricoxib. DISCUSSION Considering that positive eluate is not the typical serologic profile of drug-induced immune hemolytic anemia, developing in-house techniques to show the causal link between them may be of interest to guide the treatment and avoid the empirical use of drugs. CONCLUSION Etoricoxib must be considered as a possible cause of acute kidney failure in cases of immune hemolytic anemia.
Collapse
Affiliation(s)
- L Burgos Pratx
- Hospital Italiano de Buenos Aires. Transfusion Medicine Service, Buenos Aires, Argentina
| | - D Santoro
- Hospital Italiano de Buenos Aires. Transfusion Medicine Service, Buenos Aires, Argentina
| | - B Coca Mogro
- Hospital Italiano de Buenos Aires. Transfusion Medicine Service, Buenos Aires, Argentina
| | - V L Valiente
- Hospital Italiano de Buenos Aires. Transfusion Medicine Service, Buenos Aires, Argentina
| | - P Camino
- Hospital Italiano de Buenos Aires. Transfusion Medicine Service, Buenos Aires, Argentina
| | - W Scordo
- Hospital Italiano de Buenos Aires. Transfusion Medicine Service, Buenos Aires, Argentina
| | - H Salamone
- Hospital Italiano de Buenos Aires. Transfusion Medicine Service, Buenos Aires, Argentina
| |
Collapse
|
5
|
Summa NM, Guzman DSM, Larrat S, Troncy E, Bird DM, Lair S, Fitzgerald, G. Evaluation of High Dosages of Oral Meloxicam in American Kestrels (Falco sparverius). J Avian Med Surg 2017. [DOI: 10.1647/2015-150] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
6
|
Svennebring A. The role of intramolecular self-destruction of reactive metabolic intermediates in determining toxicity. J Appl Toxicol 2015; 36:483-500. [DOI: 10.1002/jat.3248] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2015] [Accepted: 08/27/2015] [Indexed: 12/17/2022]
Affiliation(s)
- Andreas Svennebring
- Department of Pharmaceutical Biosciences, Faculty of Pharmacy; Uppsala University; Box 591 Uppsala 751 24 Sweden
| |
Collapse
|
7
|
Xiao X, Chang C. Diagnosis and classification of drug-induced autoimmunity (DIA). J Autoimmun 2014; 48-49:66-72. [PMID: 24456934 DOI: 10.1016/j.jaut.2014.01.005] [Citation(s) in RCA: 53] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2013] [Accepted: 11/13/2013] [Indexed: 12/17/2022]
Abstract
Since sulfadiazine associated lupus-like symptoms were first described in 1945, certain drugs have been reported to interfere with the immune system and induce a series of autoimmune diseases (named drug-induced autoimmunity, DIA), exemplified by systemic lupus erythematosus (SLE). Among the drugs, procainamide and hydralazine are considered to be associated with the highest risk for developing lupus, while quinidine has a moderate risk, and all other drugs have low or very low risk. More recently, drug-induced lupus has been associated with the use of newer biological modulators, such as tumor necrosis factor (TNF)-alpha inhibitors and cytokines. In addition to lupus, other major autoimmune diseases, including vasculitis and arthritis, have also been associated with drugs. Because resolution of symptoms generally occurs after cessation of the offending drugs, early diagnosis is crucial for treatment strategy and improvement of prognosis. Unfortunately, it is difficult to establish standardized criteria for DIA diagnosis. Diagnosis of DIA requires identification of a temporal relationship between drug administration and the onset of symptoms, but the relative risk with respect to dose and duration for each drug has rarely been determined. DIA is affected by multiple genetic and environmental factors, leading to difficulties in establishing a list of global clinical features that are characteristic of most or all DIA patients. Moreover, the distinction between authentic DIA and unmasking of a latent autoimmune disease also poses challenges. In this review, we summarize the highly variable clinical features and laboratory findings of DIA, with an emphasis on the diagnostic criteria.
Collapse
Affiliation(s)
- Xiao Xiao
- Shanghai Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai Institute of Digestive Disease, 145 Shandong Middle Road, Shanghai 200001, China
| | - Christopher Chang
- Division of Allergy, Asthma and Immunology, Thomas Jefferson University, Wilmington, DE 19803, USA.
| |
Collapse
|
8
|
Zbidah M, Lupescu A, Yang W, Bosc A, Jilani K, Shaik N, Lang F. Sulindac sulfide--induced stimulation of eryptosis. Cell Physiol Biochem 2012. [PMID: 23202471 DOI: 10.1159/000341483] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023] Open
Abstract
BACKGROUND Sulindac sulfide, a non-steroidal anti-inflammatory drug (NSAID), stimulates apoptosis of tumor cells and is thus effective against malignancy. In analogy to apoptosis of nucleated cells, erythrocytes may undergo eryptosis, an apoptosis-like suicidal erythrocyte death, characterized by cell shrinkage and cell membrane scrambling with phosphatidylserine-exposure at the cell surface. Stimulators of eryptosis include increase of cytosolic Ca(2+)-activity ([Ca(2+)](i)) and ceramide formation. The present study explored, whether sulindac sulfide stimulates eryptosis. METHODS [Ca(2+)](i) was estimated from Fluo-3 fluorescence, cell volume from forward scatter, phosphatidylserine-exposure from binding of fluorescent annexin-V, hemolysis from hemoglobin release, and ceramide abundance utilizing fluorescent antibodies. RESULTS A 48 h exposure to sulindac sulfide (≤ 20 µM) was followed by significant increase of [Ca(2+)](i), enhanced ceramide abundance, decreased forward scatter and increased percentage of annexin-V-binding erythrocytes. Sulindac sulfide triggered slight but significant hemolysis. Removal of extracellular Ca(2+) significantly blunted, but did not abrogate the effect of sulindac sulfide (20 µM) on annexin-V-binding. CONCLUSION Sulindac sulfide stimulates the suicidal death of erythrocytes or eryptosis, an effect paralleled by Ca(2+)-entry, ceramide formation, cell shrinkage and phosphatidylserine-exposure.
Collapse
Affiliation(s)
- Mohanad Zbidah
- Department of Physiology, University of Tuebingen, Tuebingen, Germany
| | | | | | | | | | | | | |
Collapse
|
9
|
PHILIPPOVA TO, GALKIN BN, GOLOVENKO NYA, ZHILINA ZI, VODZINSKII SV. The protective properties of synthetic porphyrin tin complexes in toxic hyperbilirubinemia. J PORPHYR PHTHALOCYA 2012. [DOI: 10.1002/(sici)1099-1409(200004/05)4:3<243::aid-jpp201>3.0.co;2-d] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Tin complexes of meso-substituted synthetic porphyrins, namely Sn4+-meso-tetraphenyl- porphyrin ( Sn - TPP ) and Sn4+-meso-tetrakis(N-methyl-3-pyridyl)porphyrin tetratosylate ( Sn - TMe -3- PyP ), efficiently decrease the serum bilirubin level when injected subcutaneously at a dose of 100 μM kg−1body weight into mice. These compounds are active during hyperbilirubinemia, induced by phenylhydrazine, hemin and tetrachloromethane, and also during autoimmune hemolytic anemia. In the latter case a decrease in serum bilirubin content was observed, as well as a decrease in the amount of blood reticulocytes which reflects a milder course of the disease. The Sn complexes under study induce, in vivo, cytochrome P-450, inhibit microsomal heme oxygenase and decrease the intensity of lipid peroxidation. At the same time, in vitro the hepatic and splenic heme oxygenase activity is blocked only when a 0.1 μM concentration of Sn - TMe -3- PyP or Sn -protoporphyrin IX is added to the incubation mixture. Sn - TPP does not affect the activity of this enzyme in vitro.
Collapse
|
10
|
Abstract
Splenomegaly results from different abnormal conditions susceptible to drugs. Their diagnosis is based on a history of exposure to a drug before the spleen enlargement. This paper reviews studies on drugs that may induce to splenomegaly. Drugs may provoke the enlargement of the spleen by direct effect on splenic cells or as a side effect of disturbances in other organs, such as the liver, or systems, such as the haematoimmunological system. Some drugs provoke severe haemolysis associated with splenomegaly. Another cause of spleen increasing in size is the venous congestion due to liver disturbance with portal vein occlusion as side complications of drugs. All these drug side effects are usually transitory and splenomegaly disappears when the medication is discontinued. This is a complex problem that must be better studied to be understood in order to prevent its occurrence and to find the best treatment.
Collapse
Affiliation(s)
- Andy Petroianu
- Federal University of Minas Gerais, Department of Surgery, Avenida Afonso Pena, Belo Horizonte, MG 30130-005, Brazil.
| |
Collapse
|
11
|
Shimizu M, Tatsuno M, Matsushita R, Totsuka J, Inoue Y, Ohta K, Kuniya K, Fujii N, Fukasawa Y, Watanabe N, Iwata E, Miyazaki M, Hoshino M, Onda M, Matsumura M, Kikuchi Y, Yamamoto C, Hamada M, Tsuyuki A, Furuta T, Kadokura C, Kamiyama Y, Kitahara G, Suzuki K, Sejima E, Matsumoto Y, Fukuoka M. Correlation between the physicochemical property of some nonsteroidal anti-inflammatory drugs and changes in adenosine triphosphate, glutathione and hemoglobin in rat erythrocytes. Biol Pharm Bull 2003; 26:1155-65. [PMID: 12913268 DOI: 10.1248/bpb.26.1155] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
This study was conducted to explore the relationship between physicochemical property and toxic effectiveness using rat red blood cells (RBCs). The toxic effectiveness of acid nonsteroidal anti-inflammatory drugs (NSAIDs) was systemically examined by the depletion of intracorpuscular adenosine triphosphate (ATP), glutathione (GSH), and hemoglobin (Hb) at various doses, increased every 5 fmol/RBC. When the RBCs were incubated with NSAIDs, the drugs attained maximum levels within RBC, and the levels were then reduced. The ATP depletion seemed to be observed on the excretion of the drugs prior to the depletions of GSH and Hb. The physicochemical properties of NSAIDs were obtained from QMPRPlus, SMILES code, and CS ChemRaw Ultra. Correlation between their physicochemical properties and their doses for the depletions of ATP, GSH and Hb was performed in comparison with those of the membrane bound enzyme (MBE) inhibiting- and methemoglobin (MHb)-generating drugs. The ATP depletion by NSAIDs was correlated with the GSH depletion and intracorpuscular levels of the drugs, but not with the Hb depletion. The GSH depletion was correlated with the Hb depletion and participated in the lipophilicity of the drugs.
Collapse
Affiliation(s)
- Makiko Shimizu
- Department of Clinical Pharmacology and Toxicology, Showa Pharmaceutical University, Tokyo, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Abstract
The metabolic conjugation of exogenous and endogenous carboxylic acid substrates with endogenous glucuronic acid, mediated by the uridine diphosphoglucuronosyl transferase (UGT) superfamily of enzymes, leads to the formation of acyl glucuronide metabolites. Since the late 1970s, acyl glucuronides have been increasingly identified as reactive electrophilic metabolites, capable of undergoing three reactions: intramolecular rearrangement, hydrolysis, and intermolecular reactions with proteins leading to covalent drug-protein adducts. This essential dogma has been accepted for over a decade. The key question proposed by researchers, and now the pharmaceutical industry, is: does or can the covalent modification of endogenous proteins, mediated by reactive acyl glucuronide metabolites, lead to adverse drug reactions, perhaps idiosyncratic in nature? This review evaluates the evidence for acyl glucuronide-derived perturbation of homeostasis, particularly that which might result from the covalent modification of endogenous proteins and other macromolecules. Because of the availability of acyl glucuronides for test tube/in vitro experiments, there is now a substantial literature documenting their rearrangement, hydrolysis and covalent modification of proteins in vitro. It is certain from in vitro experiments that serum albumin, dipeptidyl peptidase IV, tubulin and UGTs are covalently modified by acyl glucuronides. However, these in vitro experiments have been specifically designed to amplify any interference with a biological process in order to find biological effects. The in vivo situation is not at all clear. Certainly it must be concluded that all humans taking carboxylate drugs that form reactive acyl glucuronides will form covalent drug-protein adducts, and it must also be concluded that this in itself is normally benign. However, there is enough in vivo evidence implicating acyl glucuronides, which, when backed up by in vivo circumstantial and documented in vitro evidence, supports the view that reactive acyl glucuronides may initiate toxicity/immune responses. In summary, though acyl glucuronide-derived covalent modification of endogenous macromolecules is well-defined, the work ahead needs to provide detailed links between such modification and its possible biological consequences.
Collapse
Affiliation(s)
- Mark J Bailey
- Department of Medicine, Centre for Studies in Drug Disposition, The University of Queensland at Royal Brisbane Hospital, Queensland 4029, Australia
| | | |
Collapse
|
13
|
Papich MG. Pharmacologic considerations for opiate analgesic and nonsteroidal anti-inflammatory drugs. Vet Clin North Am Small Anim Pract 2000; 30:815-37, vii. [PMID: 10932827 DOI: 10.1016/s0195-5616(08)70009-3] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
When administering opioid analgesic drugs or nonsteroidal anti-inflammatory drugs, veterinarians are often not familiar enough with the underlying pharmacology of the drugs, particularly with the potential for drug interactions and adverse effects. This article considers some of the pharmacologic features of these drugs and provides a basis for important interactions, contraindications, and adverse effects.
Collapse
Affiliation(s)
- M G Papich
- College of Veterinary Medicine, North Carolina State University, Raleigh, USA.
| |
Collapse
|
14
|
Cunha PD, Lord RS, Johnson ST, Wilker PR, Aster RH, Bougie DW. Immune hemolytic anemia caused by sensitivity to a metabolite of etodolac, a nonsteroidal anti-inflammatory drug. Transfusion 2000; 40:663-8. [PMID: 10864985 DOI: 10.1046/j.1537-2995.2000.40060663.x] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
BACKGROUND Immune hemolytic anemia can be caused by sensitivity to many different drugs. In some instances, the sensitizing compound can be identified by in vitro testing, but results are often negative. One reason for this is that a drug metabolite formed in vivo can be the sensitizing agent, but the responsible metabolites have rarely been identified at a chemical level. This report describes a patient who developed severe, Coombs-positive hemolytic anemia on two occasions after taking the nonsteroidal anti-inflammatory drug etodolac. Studies were performed to characterize etodolac metabolites to which this patient was sensitive. CASE REPORT Serum was tested for antibody in the presence and absence of drug using conventional methods and urine from individuals taking etodolac as a source of drug metabolites. Urinary metabolites of etodolac were identified by high-pressure liquid chromatography analysis. Glucuronide conjugates of etodolac and the 6-OH metabolite of etodolac were synthesized in a rat liver microsomal system to obtain reference standards. RESULTS The patient's serum gave only trace (+/-) reactions with normal RBCs in the presence of etodolac but reacted strongly (4+) in the presence of urine from an individual taking this drug. The active urinary metabolites were identified as etodolac glucuronide and 6-OH etodolac glucuronide. CONCLUSION This patient appears to have experienced acute, severe immune hemolytic anemia on two occasions because of sensitivity to the glucuronides of etodolac and 6-OH etodolac. In patients suspected of having drug-induced immune hemolytic anemia, RBC-reactive antibodies can sometimes be detected by using urine from an individual taking the implicated medication as the source of drug metabolites in in vitro reactions. For patients who present with acute immune hemolysis, a careful history of drug exposure should be taken, and, where indicated, confirmatory testing should be performed to identify the sensitizing drug and prevent inadvertent reinduction of hemolysis at a later time.
Collapse
Affiliation(s)
- P D Cunha
- West Michigan Cancer Center, Kalamazoo, Michigan, USA
| | | | | | | | | | | |
Collapse
|
15
|
Rubio-Martinez A, Garcia-Erce JA, Salvador C, Gomez-Arteta E, Gimeno J. Autoimmune Haemolytic Anaemia Induced by Propyphenazone. Vox Sang 1998. [DOI: 10.1046/j.1423-0410.1998.75302571.x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
16
|
Jones K. Points: Postperinatal mortality in a health district with a garrison town. West J Med 1988. [DOI: 10.1136/bmj.297.6653.921-a] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
17
|
Dewhurst JK. The code for promoting drugs. West J Med 1988. [DOI: 10.1136/bmj.297.6653.920-d] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
18
|
Shapiro JA. Points: Postperinatal mortality in a health district with a garrison town. West J Med 1988. [DOI: 10.1136/bmj.297.6653.921] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
19
|
Saunders KB. Points: Drug rationalisation programme in hospital. West J Med 1988. [DOI: 10.1136/bmj.297.6653.921-c] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
20
|
Brattebo G. Points: Occult biochemical pregnancies. West J Med 1988. [DOI: 10.1136/bmj.297.6653.921-b] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
21
|
|
22
|
Martland T, Stone WD. Haemolytic anaemia associated with fenbufen. BMJ (CLINICAL RESEARCH ED.) 1988; 297:921. [PMID: 3140989 PMCID: PMC1834437 DOI: 10.1136/bmj.297.6653.921-e] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
|
23
|
Abstract
Despite a continuing lack of good quality epidemiological studies, our knowledge of the side-effects of NSAIDs has advanced in recent years. The most important reactions are those which are related predictably to the pharmacology of the drugs and these need to be considered whenever a NSAID is prescribed, particularly for patients who can be identified as belonging to high-risk groups. The important reactions are: 1. Gastrointestinal damage, which is now known to extend to some degree from the oesophagus to the rectum, although the acid contact areas of the stomach and duodenum are the most important. Although the studies have produced heterogeneous results, NSAIDs probably double or triple the risk of an individual developing serious gastrointestinal haemorrhage or perforation. The risk increases with age and previous history of ulceration, and, in communities with particularly high use of NSAIDs, the drugs may account for up to 30% of all cases of ulcer complications. 2. Renal syndromes, of which functional renal impairment is the most important. This may precipitate cardiac failure, and hyperkalaemia is an additional hazard. Antagonism of the action of diuretics may contribute to the fluid retention, and antagonism of antihypertensive therapy is probably quite common and may result in additional unnecessary therapy. Patients at risk of functional renal impairment from NSAIDs can be identified readily and in these subjects the drugs have to be used with great care and with appropriate monitoring. 3. Respiratory effects, in particular acute bronchospasm in subjects with a history of aspirin sensitivity. NSAIDs should be used with caution in asthmatics, and patients purchasing NSAIDs without prescriptions need to be warned of these effects. Other uncommon serious reactions include hepatocellular damage, acute interstitial nephritis, agranulocytosis and aplastic anaemia, Stevens-Johnson syndrome and toxic epidermal necrolysis. These are unpredictable reactions which generally need not be considered before prescribing. However, in patients who present with any of these conditions, NSAIDs, because of their wide use, should always be considered as a possible cause.
Collapse
|